moomoo ID:NaN
Log Out
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > AVTX Avalo Therapeutics > Company Executives
AVTX Avalo Therapeutics
NamePositionSalaryService DateEducationAgeGenderUpdated
Dr. Garry A. Neil, M.D.Chairman of the Board, President and Chief Executive Officer2.69M----68male08/11/2022
Dr. H. Jeffrey WilkinsChief Medical Officer1.25M----59male02/08/2022
Mr. Christopher Ryan SullivanChief Financial Officer and Principal Accounting Officer------37male04/25/2022
Dr. Simon C. Pedder, PhDDirector47.10K----59male04/28/2020
Dr. Gilla Kaplan,PhDIndependent Director153.98K----75female04/25/2022
Dr. June S. Almenoff, F.A.C.P.,M.D.,PhDIndependent Director138.09K----65female04/25/2022
Dr. Magnus Persson, M.D.,PhDLead Independent Director167.98K----61male04/25/2022
Mr. Mitchell ChanIndependent Director111.30K----41male04/25/2022
Company Overview More
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
CEO: Dr. Garry A. Neil, M.D.
Market: NASDAQ
Listing Date: 11/13/2015
Hot List
SymbolLatest price%Chg